Flow Research

Phenylpiracetam: 200mg

  1. Zvejniece, Liga et al. “S-phenylpiracetam, a selective DAT inhibitor, reduces body weight gain without influencing locomotor activity.” Pharmacology, biochemistry, and behavior vol. 160 (2017): 21-29. doi:10.1016/j.pbb.2017.07.009

  1. Malykh, Andrei G, and M Reza Sadaie. “Piracetam and piracetam-like drugs: from basic science to novel clinical applications to CNS disorders.” Drugs vol. 70,3 (2010): 287-312. doi:10.2165/11319230-000000000-00000

  1. Vernon, M W, and E M Sorkin. “Piracetam. An overview of its pharmacological properties and a review of its therapeutic use in senile cognitive disorders.” Drugs & aging vol. 1,1 (1991): 17-35. doi:10.2165/00002512-199101010-00004

  1. Gouliaev, A H, and A Senning. “Piracetam and other structurally related nootropics.” Brain research. Brain research reviews vol. 19,2 (1994): 180-222. doi:10.1016/0165-0173(94)90011-6

  1. Vernon, Margaret W., and Eugene M. Sorkin. "Piracetam." Drugs & aging 1.1 (1991): 17-35.

Alpha GPC: 300mg

  1. PM, Kidd (2009) “Integrated brain restoration after ischemic stroke-medical management, risk factors, nutrients, and other interventions for managing inflammation and Enhancing Brain Plasticity” Alternative Medicine Review, 2009 - Thorne Research Inc.
  2. Marcus, Lena et al. “Evaluation of the effects of two doses of alpha glycerylphosphorylcholine on physical and psychomotor performance.” Journal of the International Society of Sports Nutrition vol. 14 39. 5 Oct. 2017, doi:10.1186/s12970-017-0196-5

  1. Bellar, David et al. “The effect of 6 days of alpha glycerylphosphorylcholine on isometric strength.” Journal of the International Society of Sports Nutrition vol. 12 42. 17 Nov. 2015, doi:10.1186/s12970-015-0103-x

  1. Ziegenfuss, Tim, Jamie Landis, and Jennifer Hofheins. "Acute supplementation with alpha-glycerylphosphorylcholine augments growth hormone response to, and peak force production during, resistance exercise." Journal of the International Society of Sports Nutrition 5.S1 (2008): P15.
  2. Strifler, Gerda et al. “Targeting Mitochondrial Dysfunction with L-Alpha Glycerylphosphorylcholine.” PloS one vol. 11,11 e0166682. 18 Nov. 2016, doi:10.1371/journal.pone.0166682

Huperzine A: 5mcg

  1. Wang, Rui, and Xi Can Tang. "Neuroprotective effects of huperzine A." Neurosignals 14.1-2 (2005): 71-82.

  1. Yang, Guoyan et al. “Huperzine A for Alzheimer's disease: a systematic review and meta-analysis of randomized clinical trials.” PloS one vol. 8,9 e74916. 23 Sep. 2013, doi:10.1371/journal.pone.0074916

  1. Gul, Amara et al. “Huperzine-A response to cognitive impairment and task switching deficits in patients with Alzheimer's disease.” Journal of the Chinese Medical Association : JCMA, S1726-4901(18)30226-0. 7 Sep. 2018, doi:10.1016/j.jcma.2018.07.004

  1. Damar, U et al. “Huperzine A as a neuroprotective and antiepileptic drug: a review of preclinical research.” Expert review of neurotherapeutics vol. 16,6 (2016): 671-80. doi:10.1080/14737175.2016.1175303

  1. Damar, Ugur et al. “Huperzine A: A promising anticonvulsant, disease modifying, and memory enhancing treatment option in Alzheimer's disease.” Medical hypotheses vol. 99 (2017): 57-62. doi:10.1016/j.mehy.2016.12.006

Acetyl L-carnitine: 300mg

  1. Ferreira, Gustavo C, and Mary C McKenna. “L-Carnitine and Acetyl-L-carnitine Roles and Neuroprotection in Developing Brain.” Neurochemical research vol. 42,6 (2017): 1661-1675. doi:10.1007/s11064-017-2288-7

  1. Nasca, Carla et al. “Acetyl-l-carnitine deficiency in patients with major depressive disorder.” Proceedings of the National Academy of Sciences of the United States of America vol. 115,34 (2018): 8627-8632. doi:10.1073/pnas.1801609115

  1. Sergi, G et al. “Effects of acetyl-L-carnitine in diabetic neuropathy and other geriatric disorders.” Aging clinical and experimental research vol. 30,2 (2018): 133-138. doi:10.1007/s40520-017-0770-3

  1. Mohammadi, Rahim, and Keyvan Amini. “Topically-administered acetyl-L-carnitine increases sciatic nerve regeneration and improves functional recovery after tubulization of transected short nerve gaps.” Journal of neurosurgical sciences vol. 61,4 (2017): 395-402. doi:10.23736/S0390-5616.16.02845-9

  1. Pettegrew, Jay W., et al. "Clinical and neurochemical effects of acetyl-L-carnitine in Alzheimer's disease." Neurobiology of aging 16.1 (1995): 1-4.

Rhodiola Rosea: 200mg

  1. Amsterdam, Jay D, and Alexander G Panossian. “Rhodiola rosea L. as a putative botanical antidepressant.” Phytomedicine : international journal of phytotherapy and phytopharmacology vol. 23,7 (2016): 770-83. doi:10.1016/j.phymed.2016.02.009

  1. Nabavi, Seyed Fazel et al. “Rhodiola rosea L. and Alzheimer's Disease: From Farm to Pharmacy.” Phytotherapy research : PTR vol. 30,4 (2016): 532-9. doi:10.1002/ptr.5569

  1. Panossian, A et al. “Rosenroot (Rhodiola rosea): traditional use, chemical composition, pharmacology and clinical efficacy.” Phytomedicine : international journal of phytotherapy and phytopharmacology vol. 17,7 (2010): 481-93. doi:10.1016/j.phymed.2010.02.002

  1. Ishaque, Sana et al. “Rhodiola rosea for physical and mental fatigue: a systematic review.” BMC complementary and alternative medicine vol. 12 70. 29 May. 2012, doi:10.1186/1472-6882-12-70

  1. Li, Yonghong et al. “Rhodiola rosea L.: an herb with anti-stress, anti-aging, and immunostimulating properties for cancer chemoprevention.” Current pharmacology reports vol. 3,6 (2017): 384-395. doi:10.1007/s40495-017-0106-1

Bacopa Monnieri: 100mg

  1. Nemetchek, Michelle D et al. “The Ayurvedic plant Bacopa monnieri inhibits inflammatory pathways in the brain.” Journal of ethnopharmacology vol. 197 (2017): 92-100. doi:10.1016/j.jep.2016.07.073

  1. Kongkeaw, Chuenjid et al. “Meta-analysis of randomized controlled trials on cognitive effects of Bacopa monnieri extract.” Journal of ethnopharmacology vol. 151,1 (2014): 528-35. doi:10.1016/j.jep.2013.11.008

  1. Chaudhari, Kaustubh S et al. “Neurocognitive Effect of Nootropic Drug Brahmi (Bacopa monnieri) in Alzheimer's Disease.” Annals of neurosciences vol. 24,2 (2017): 111-122. doi:10.1159/000475900

  1. Kwon, Hyun Jung et al. “Bacopa monnieri extract improves novel object recognition, cell proliferation, neuroblast differentiation, brain-derived neurotrophic factor, and phosphorylation of cAMP response element-binding protein in the dentate gyrus.” Laboratory animal research vol. 34,4 (2018): 239-247. doi:10.5625/lar.2018.34.4.239

  1. Abdul Manap, Aimi Syamima et al. “Bacopa monnieri, a Neuroprotective Lead in Alzheimer Disease: A Review on Its Properties, Mechanisms of Action, and Preclinical and Clinical Studies.” Drug target insights vol. 13 1177392819866412. 31 Jul. 2019, doi:10.1177/1177392819866412

Noopept: 10mg

  1. Ostrovskaya, Rita U., et al. "The nootropic and neuroprotective proline-containing dipeptide noopept restores spatial memory and increases immunoreactivity to amyloid in an Alzheimer's disease model." Journal of psychopharmacology 21.6 (2007): 611-619.

  1. Ostrovskaya, Rita U et al. “Neuroprotective effect of novel cognitive enhancer noopept on AD-related cellular model involves the attenuation of apoptosis and tau hyperphosphorylation.” Journal of biomedical science vol. 21,1 74. 6 Aug. 2014, doi:10.1186/s12929-014-0074-2

  1. Antipova, T. A., et al. "Dipeptide Piracetam Analogue Noopept Improves Viability of Hippocampal HT-22 Neurons in the Glutamate Toxicity Model." Bulletin of experimental biology and medicine 161.1 (2016): 58-60.

  1. Boiko, S S et al. “Pharmacokinetics of new nootropic acylprolly-dipeptide and its penetration across the blood-brain barrier after oral administration.” Bulletin of experimental biology and medicine vol. 129,4 (2000): 359-61. doi:10.1007/bf02439270

  1. Gharibyan, Anna. Amyloids here, amyloids there… What’s wrong with them?. Diss. Umeå University, 2012.

CoQ10: 20mg

  1. Sarmiento, Alvaro et al. “Coenzyme Q10 Supplementation and Exercise in Healthy Humans: A Systematic Review.” Current drug metabolism vol. 17,4 (2016): 345-58. doi:10.2174/1389200216666151103115654

  1. Hargreaves, Iain P, and David Mantle. “Coenzyme Q10 Supplementation in Fibrosis and Aging.” Advances in experimental medicine and biology vol. 1178 (2019): 103-112. doi:10.1007/978-3-030-25650-0_6

  1. Sharma, Abhinav et al. “Coenzyme Q10 and Heart Failure: A State-of-the-Art Review.” Circulation. Heart failure vol. 9,4 (2016): e002639. doi:10.1161/CIRCHEARTFAILURE.115.002639


  1. Mantle, David, and Iain Hargreaves. “Coenzyme Q10 and Degenerative Disorders Affecting Longevity: An Overview.” Antioxidants (Basel, Switzerland) vol. 8,2 44. 16 Feb. 2019, doi:10.3390/antiox8020044

  1. Flowers, Nadine et al. “Co-enzyme Q10 supplementation for the primary prevention of cardiovascular disease.” The Cochrane database of systematic reviews ,12 (2014): CD010405. doi:10.1002/14651858.CD010405.pub2


bioperine 10mg

  1. https://www.bioperine.com/index.php/researchhighlight

  1. Peterson, Christine T et al. “Effects of Turmeric and Curcumin Dietary Supplementation on Human Gut Microbiota: A Double-Blind, Randomized, Placebo-Controlled Pilot Study.” Journal of evidence-based integrative medicine vol. 23 (2018): 2515690X18790725. doi:10.1177/2515690X18790725

  1. Vasto, Sonya et al. “Dietary Supplements as Surrogate of Mediterranean Diet in Healthy Smoking Subjects.” Rejuvenation research vol. 21,1 (2018): 37-43. doi:10.1089/rej.2017.1950

  1. https://www.bioperine.com/index.php/mechanismsofactions